"Vaginal rejuvenation" is a marketing term, not a diagnosis. It is slapped onto everything from legitimate treatment of a real menopause condition to cosmetic procedures with no medical purpose, which is exactly why the category became a regulatory problem. The real condition behind much of the demand is genitourinary syndrome of menopause (GSM) — the thinning, drying, and loss of elasticity of vaginal and vulvar tissue (and related urinary symptoms) caused by the loss of estrogen at menopause. Unlike hot flashes, GSM usually worsens over time without treatment and can cause pain with sex, burning, irritation, and recurrent urinary tract infections. It is common, under-treated, and genuinely treatable.
The problem this article untangles is that the energy-based devices most aggressively marketed for it — fractional CO₂ lasers like MonaLisa Touch, radiofrequency devices like ThermiVa, and related platforms — are FDA-cleared for general gynecologic soft-tissue use but are not cleared or approved for treating GSM, vaginal dryness, urinary incontinence, or sexual function. In July 2018 the FDA issued a specific safety warning about exactly this mismatch, and major gynecologic societies agreed. That does not mean the devices cannot help anyone — the evidence is genuinely mixed and still evolving — but it means the marketing and the clearance are two different things, and a patient should understand both before paying. This article is educational and not a substitute for care from a gynecologist or menopause-trained clinician.
The FDA action that defines this category
On July 30, 2018, FDA Commissioner Scott Gottlieb issued a safety communication warning that the agency "has not cleared or approved for marketing any energy-based devices" to treat symptoms or conditions related to menopause, urinary incontinence, or sexual function — including vaginal laxity, vaginal atrophy, dryness, itching, and pain during sex. The devices in question (fractional CO₂ lasers and radiofrequency platforms) had been cleared for legitimate uses like the ablation or vaporization of soft tissue in gynecology, but manufacturers were promoting them "deceptively" for menopause and sexual-function claims that had never been evaluated. The FDA cited reports of serious adverse events: vaginal burns, scarring, painful intercourse, and chronic or recurring pain.
The agency followed the warning with letters to seven specific manufacturers — Alma Lasers, BTL Aesthetics, BTL Industries, Cynosure, InMode, Sciton, and Thermigen. The letter to Cynosure, maker of MonaLisa Touch (the DEKA SmartXide2 system), is instructive: the device was cleared under K133895 for incision, excision, ablation, vaporization, and coagulation of soft tissue across medical specialties including gynecology — not for "the painful symptoms of menopause" or any GSM indication, which the manufacturer had nonetheless claimed on its website. To be precise about what is cleared: these energy-based devices have FDA clearance for treating things like abnormal or precancerous cervical or vaginal tissue and genital warts — not for vaginal dryness, atrophy, laxity, urinary incontinence, or sexual function. The practical translation for a patient today: the device is legally in the office, but the menopause claim it was sold on is an off-label, unapproved use.
A typical course, as clinics describe it, is three sessions spaced roughly six weeks apart, each lasting only a few minutes, with annual or 12–18-month maintenance sessions to sustain any benefit. That protocol detail is worth knowing because it frames the cost and commitment — and because the durability of effect past the maintenance window is one of the things the longer-term evidence has not nailed down.
What the devices are, mechanically
These are not magic wands; they deliver controlled energy to vaginal tissue on the theory that thermal injury stimulates collagen remodeling, thickens the mucosa, and improves moisture and elasticity.
- Fractional CO₂ lasers (MonaLisa Touch/DEKA SmartXide2, FemiLift, Diva) create microscopic columns of thermal injury in the vaginal wall. CO₂ is an ablative chromophore-for-water technology — the same family as the resurfacing lasers covered in our CO₂ vs. Er:YAG comparison, here delivered internally.
- Erbium:YAG lasers (Fotona Smooth) use a gentler, non-ablative wavelength and are marketed as a "second-generation" vaginal laser.
- Radiofrequency (RF) devices (ThermiVa, Viveve/Geneveve) heat tissue more broadly, sometimes with surface cooling, rather than ablating it — analogous in mechanism to the RF tightening covered in our non-surgical skin-tightening overview, applied to vaginal tissue.
- Emsella (BTL) is different again: a high-intensity focused electromagnetic (HIFEM) chair that stimulates thousands of supramaximal pelvic-floor contractions, cleared for urinary incontinence and pitched for "wellness."
The mechanism stories are plausible. The question is whether they translate into durable, reproducible symptom relief that beats standard therapy — and on that, the evidence is unsettled.
What the evidence actually shows
The honest summary is that vaginal laser and RF for GSM is a contested, evolving evidence base, not a settled one. Open-label (unblinded) studies and many real-world series report improvements in dryness, dyspareunia, and vaginal health index scores, which is why enthusiastic clinics and breast-cancer survivors who cannot use estrogen are drawn to them. But when researchers run sham-controlled randomized trials — where some patients get the real treatment and others get a convincing fake — the results are mixed, and several societies have concluded the benefit is unproven outside of clinical trials. Because GSM has a large placebo response and fluctuates with sexual activity and lubricant use, unblinded results overstate real benefit.
This is why positioning matters more than a single study's percentage. In August 2018, the International Society for the Study of Vulvovaginal Disease (ISSVD) and the International Continence Society (ICS) issued a joint statement supporting the FDA warning and explicitly recommending against laser and radiofrequency for lichen sclerosus, vulvodynia, urinary incontinence, vulvovaginal atrophy, or "rejuvenation," except inside properly designed clinical trials. The Menopause Society (formerly NAMS), in its patient guidance updated in 2025, states plainly that vaginal laser and RF are FDA-cleared for vaginal use but not specifically for GSM, and that "the evidence does not strongly support their use" for vulvovaginal dryness, discomfort, or pain — advising patients these methods are experimental outside trials. A 2022 STAT perspective by a breast surgical oncologist went further, calling for the FDA to restrict the use. That is not a fringe position; it is the mainstream gynecologic-society position.
What is actually first-line for GSM
The treatments with the strongest evidence and explicit guideline backing predate the lasers by decades:
- Non-hormonal first line for mild symptoms: vaginal lubricants (used with sexual activity) and long-acting vaginal moisturizers (used several times a week), all over the counter.
- Low-dose vaginal estrogen (creams such as Estrace or Premarin; the Estring vaginal ring; Vagifem or Imvexxy tablets) is the prescription workhorse for GSM. Delivered vaginally, systemic absorption is low, and no progestin is generally needed for endometrial protection at these doses.
- Vaginal DHEA (prasterone, Intrarosa) — a nightly 6.5 mg vaginal insert converted locally to estrogen and androgen.
- Oral ospemifene (Osphena) — a selective estrogen-receptor modulator (SERM) tablet for moderate-to-severe dyspareunia and dryness, for women who prefer a non-vaginal route.
- Systemic hormone therapy when GSM accompanies bothersome hot flashes, per the 2022 Menopause Society hormone-therapy position statement.
A note for breast-cancer survivors: this is the population most often steered toward laser precisely because estrogen is off the table. The ISSWSH 2020 GSM position statement notes that clinical-trial data on laser in breast-cancer survivors provides only limited safety and efficacy evidence, and that vaginal DHEA labeling advises caution because estrogen is a metabolite — a decision that belongs with the oncology team, not a med-spa promotional video.
What it costs and how to think about it
Because these devices are used off-label for GSM, treatment is almost always cash-pay — a course typically runs roughly $1,500–$3,000 for an initial series of three sessions with annual maintenance, though pricing varies widely. Insurance does not cover off-label laser "rejuvenation." By contrast, generic vaginal estrogen cream, vaginal moisturizers, and oral ospemifene may be insurance-covered and cost a fraction of a laser course. The decision-grade question is not "is laser cheaper or more expensive" but "have I tried the evidence-based first-line therapy, and is a clinician recommending laser for my specific situation — or am I responding to marketing?" A provider who skips the first-line conversation and leads with laser is a signal, the same way we discuss provider red flags more broadly in our how-to-choose-an-injector guide.
What to ask a clinician
- Is what I have actually GSM, and have other causes (infection, lichen sclerosus, vulvodynia) been ruled out? Symptoms alone are not a diagnosis.
- What first-line therapy have I tried? Lubricants, moisturizers, and vaginal estrogen have the strongest evidence and the lowest cost.
- Is the device you're recommending FDA-cleared for GSM specifically? The honest answer is no; it is cleared for gynecologic soft-tissue use, used off-label for GSM.
- What does the relevant specialty society (The Menopause Society, ACOG, ISSVD/ICS) say about this use? They advise caution and trial-only use.
- If I have a history of breast or endometrial cancer, is this safe for me, and who cleared it with my oncology team? This population is heavily marketed to and has the most to lose.
- What are the realistic adverse events — burns, scarring, new or worsening pain — and how are they handled? These are the events the FDA flagged.
GSM is real, common, and genuinely treatable — most often with inexpensive, well-studied first-line therapy. Vaginal laser and RF devices may yet earn a defined role as the evidence matures, and they already fill a gap for some patients who cannot or will not use vaginal hormones. But in 2026, the devices sit on the wrong side of an FDA safety warning for the exact indication they are most aggressively sold for, and the major gynecologic societies treat them as experimental outside clinical trials. A patient who understands that gap makes a very different decision than one who reads the marketing.
Sources
- FDA — Statement from FDA Commissioner Scott Gottlieb on efforts to safeguard women's health from deceptive claims and significant risks related to devices marketed for "vaginal rejuvenation" (July 30, 2018 safety communication; seven manufacturers named; burns/scarring/pain): https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-claims
- FDA — Cynosure, Inc. letter regarding DEKA SmartXide2 (MonaLisa Touch), cleared K133895 for soft-tissue ablation/vaporization/coagulation, not GSM: https://www.fda.gov/files/medical%20devices/published/Cynosure--Inc.-Letter---July-24--2018.pdf
- PMC — What Is Being Reported About Vaginal "Lasers"? Examination of Adverse Events Reported to the FDA on Energy-Based Devices (2018 warning, MAUDE burns/dyspareunia/pain, registry): https://pmc.ncbi.nlm.nih.gov/articles/PMC9117087
- PMC — Energy-Based Interventions for Genitourinary Syndrome of Menopause: systematic review of RCTs and prospective studies (FDA cleared for general gynecology, not menopause symptoms; sham-controlled data): https://pmc.ncbi.nlm.nih.gov/articles/PMC12192295
- ISSVD / ICS — Joint comments on the FDA communication on energy-based devices for vaginal "rejuvenation" (Aug 5, 2018; recommend against use outside trials): https://www.issvd.org/application/files/3316/2671/5376/2018_08_05-ISSVD_ICS.pdf
- The Menopause Society — Genitourinary Syndrome of Menopause (MenoNote, updated 5/2025; laser/RF FDA-cleared for vaginal use but not GSM; first-line lubricants/moisturizers/vaginal estrogen/DHEA/ospemifene): https://menopause.org/wp-content/uploads/for-women/MenoNote-GSM.pdf
- PubMed — The 2022 Hormone Therapy Position Statement of The North American Menopause Society (vaginal estrogen/DHEA/ospemifene for GSM): https://pubmed.ncbi.nlm.nih.gov/35797481
- ISSWSH — The 2020 genitourinary syndrome of menopause position statement (stepwise therapy; breast-cancer and laser evidence limitations): https://www.isswsh.org/images/content/2020-NAMS-GSM-Paper.pdf
- AARP — FDA Warning: Laser Devices for "Vaginal Rejuvenation" (Gottlieb statement context, NAMS executive director quote on 12-week trials): https://www.aarp.org/health/conditions-treatments/vaginal-rejuvenation-laser-treatment-risks
- STAT News — The FDA needs to take another look at laser-based "vaginal rejuvenation" (2022 perspective on breast-cancer population and risk): https://www.statnews.com/2022/02/22/the-fda-needs-to-take-another-look-at-laser-based-vaginal-rejuvenation
